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1. Background {#mol212463-sec-0001}
=============

Perineural invasion (PNI) is a characteristic feature of pancreatic adenocarcinoma (PDAC), which is, upon detailed histopathology examination, encountered in almost 100% of cases (Liu, [2002](#mol212463-bib-0037){ref-type="ref"}; Marchesi *et al*., [2010](#mol212463-bib-0039){ref-type="ref"}; Pour *et al*., [2003](#mol212463-bib-0042){ref-type="ref"}). PNI correlates with tumor recurrence (Chou *et al*., [2013](#mol212463-bib-0012){ref-type="ref"}; Kayahara *et al*., [1993](#mol212463-bib-0027){ref-type="ref"}; Kelsen *et al*., [1997](#mol212463-bib-0028){ref-type="ref"}; Liu, [2002](#mol212463-bib-0037){ref-type="ref"}; Shimada *et al*., [2011](#mol212463-bib-0055){ref-type="ref"}), is implicated in generation of pain (Bapat *et al*., [2011](#mol212463-bib-0004){ref-type="ref"}; D\'Haese *et al*., [2014](#mol212463-bib-0020){ref-type="ref"}), and confers poor prognosis (Zhang *et al*., [2013](#mol212463-bib-0063){ref-type="ref"}). However, despite the first description of PNI more than 150 years ago (Demir *et al*., [2012a](#mol212463-bib-0017){ref-type="ref"}) and its doubtless importance, it is still the least studied route of metastatic spread, and our knowledge of the neuro‐epithelial interactions in PDAC remains limited and fragmented. Recent reports indicated that the microenvironment created by this interaction provides a suitable milieu for tumor growth, resulting in enhanced proliferation and inhibition of apoptosis as well as increased migration of cancer cells (Bapat *et al*., [2011](#mol212463-bib-0004){ref-type="ref"}; Dai *et al*., [2007](#mol212463-bib-0015){ref-type="ref"}). At the same time, akin to neoangiogenesis and lymphangiogenesis, tumor cells also promote neoneurogenesis, manifested in increased nerve hypertrophy and neural density in human PDAC tissues (Ceyhan *et al*., [2009a](#mol212463-bib-0008){ref-type="ref"}). The presence and implication of alterations in the neuronal structure and/or function, that is, neuronal remodeling and plasticity, in the context of cancer are increasingly recognized (Demir *et al*., [2015](#mol212463-bib-0019){ref-type="ref"}). Moreover, neuroplastic changes are seen in early development of PDAC with ablation of sensory neurons leading to slower development of PanINs (pancreatic intraepithelial neoplasia) (Saloman *et al*., [2016](#mol212463-bib-0050){ref-type="ref"}), while in contrast, subdiaphragmatic vagotomy in LSL‐Kras+/G12D; Pdx1‐Cre (KC) mice accelerated PDAC development (Renz *et al*., [2018a](#mol212463-bib-0045){ref-type="ref"}). Furthermore, antibody targeting of NGF (nerve growth factor) or small molecule blocking of NGF‐Trk pathway led to inhibition of cancer progression and increased overall mice survival in LSL‐Kras+/G12D; LSL‐Trp53+/R172H; Pdx1‐Cre (KPC) mouse model (Renz *et al*., [2018b](#mol212463-bib-0044){ref-type="ref"}; Saloman *et al*., [2018](#mol212463-bib-0051){ref-type="ref"}). These findings confirm the important and active role of the nervous system in both PDAC development and progression as well as its potential for therapeutic targeting (Demir *et al*., [2012b](#mol212463-bib-0018){ref-type="ref"}; Jobling *et al*., [2015](#mol212463-bib-0024){ref-type="ref"}; Mancino *et al*., [2011](#mol212463-bib-0038){ref-type="ref"}; Pour *et al*., [2003](#mol212463-bib-0042){ref-type="ref"}; Saloman *et al*., [2016](#mol212463-bib-0050){ref-type="ref"}; Stopczynski *et al*., [2014](#mol212463-bib-0058){ref-type="ref"}).

Most of the observations on PNI were made using a currently limited number of *in vitro* and *in vivo* models (Amit *et al*., [2016](#mol212463-bib-0003){ref-type="ref"}; Deborde *et al*., [2018](#mol212463-bib-0016){ref-type="ref"}; Demir *et al*., [2012a](#mol212463-bib-0017){ref-type="ref"}; Liebig *et al*., [2009](#mol212463-bib-0036){ref-type="ref"}), and very few large‐scale studies of PNI tissues have been performed until now: Gene expression of microdissected PNI and non‐PNI salivary adenoid cystic carcinoma cells (Chen *et al*., [2007](#mol212463-bib-0011){ref-type="ref"}), and gene and microRNA profiles were analyzed in bulk prostate cancer tissues from cases with or without PNI (Prueitt *et al*., [2008](#mol212463-bib-0043){ref-type="ref"}). In the pancreas, transcriptome and proteome of high and low nerve‐invasive PDAC cell lines injected in NOD/SCID (nonobese diabetes/severe combined immunodeficient) mice were described (Abiatari *et al*., [2009](#mol212463-bib-0001){ref-type="ref"}; Hibi *et al*., [2009](#mol212463-bib-0023){ref-type="ref"}; Koide *et al*., [2006](#mol212463-bib-0032){ref-type="ref"}), but no large‐scale molecular data from cancer cells or nerves within PNI tissues are available as yet. Here, we report on global proteomic analysis of laser microdissected, matched PNI and non‐PNI cancer as well as invaded and noninvaded nerves from human formalin‐fixed, paraffin‐embedded (FFPE) tissues. In addition, we developed an *in vitro* model that successfully recapitulated several phenotypic and molecular alterations observed in PNI in human PDAC tissues.

2. Materials and methods {#mol212463-sec-0002}
========================

2.1. Tissues and cell lines {#mol212463-sec-0003}
---------------------------

Normal and PDAC tissues were collected and obtained from the Department of Histopathology, Royal London Hospital (London, UK), Department of Pathology and Forensic Medicine (Osijek, Croatia) and from European Pancreas Centre Research Laboratory at the University of Heidelberg (Heidelberg, Germany). All tissues were obtained with full ethical approval from the respective Institutional Boards and used in accordance with the Human Tissue Act 2004.

PDAC cell lines (MiaPaca2, BxPC3, and Capan1) were obtained from Cancer Research UK Tissue Culture Service and routinely cultured in Dulbecco\'s modified Eagle\'s medium, DMEM (Invitrogen, Paisley, UK) supplemented with 10% heat‐inactivated fetal bovine serum (FBS) (Autogen Bioclear, Wiltshire, UK) and penicillin/streptomycin at 37 °C in 5% CO~2~. PC12 cells, a rat pheochromocytoma cell line, were a kind gift from Dr Lesley Robson (Blizard Institute, QMUL London) and were grown in poly‐[d]{.smallcaps}‐lysine hydrobromide (PDL; MW 30 000--70 000, Sigma, Dorset, UK P7886) coated tissue culture flasks in RPMI media supplemented with 10% heat‐inactivated horse serum, 5% heat‐inactivated FBS, and penicillin/streptomycin at 37 °C in 5% CO~2~. The identity of the cell lines utilized was confirmed by STR profiling.

2.2. Tissue section preparation and laser microdissection {#mol212463-sec-0004}
---------------------------------------------------------

Ten‐micrometer sections were cut from each of five FFPE PDAC blocks (PDAC 1--5, Table [S1](#mol212463-sup-0006){ref-type="supplementary-material"}) and mounted on PEN membrane slides (Zeiss, Munich, Germany) (Fig. [S1](#mol212463-sup-0001){ref-type="supplementary-material"}). Every fifth section was cut at 5 μm, routinely stained with H&E, and reviewed to determine areas for laser microdissection. After baking in an oven at 55 °C for 45 min, sections on PEN slides were deparaffinized using xylene and rehydrated in graded ethanol, stained with hematoxylin, and dehydrated through graded ethanol followed by xylene and air‐drying for 5 min. The staining procedure was completed in 15 min. Laser microdissection was performed using PALM instrument (Zeiss). PNI cancer, non‐PNI cancer, invaded nerves, and noninvaded nerves were separately dissected from each of the five pancreatic cancer cases and stored at −20 °C.

2.3. Protein extraction for proteomic analysis {#mol212463-sec-0005}
----------------------------------------------

Laser microdissected samples (approximately 30 000 cells) were resuspended in 20 μL liquid tissue buffer (Expression Pathology, Inc., Rockville, MD, USA), and protein extraction and digestion were performed according to the manufacturer\'s instructions. Briefly, samples were boiled for 90 min at 95 °C, cooled on ice, and digested overnight at 37 °C with sequencing grade trypsin (Promega, Southampton, UK) (1 μg/20 μL buffer). Peptide concentration was measured with Micro BCA kit (Thermo Fisher Scientific, Waltham, MA, USA), and DTT (10 m[m]{.smallcaps} final concentration) was then added and samples were boiled at 95 °C for 5 min before storing at −20 °C until further analysis.

2.4. Proteomic analysis and data processing {#mol212463-sec-0006}
-------------------------------------------

LC‐MS/MS was performed (MSBioworks, Ann Arbor, MI, USA) on a Nanoacquity LC system coupled to LTQ Orbitrap Velos platform (Thermo Fisher) using 1 μg peptide digests of each of the five matched PNI and non‐PNI cancers and invaded and noninvaded nerves, in duplicate. Buffer A was 0.1% FA in water, and buffer B was 0.1% FA in acetonitrile. Samples which were suspended in 0.1% FA were first loaded on an IntegraFrit trap column (75 μm × 30 mm) packed with Jupiter Proteo C12 material with 5 μm particle size (Thermo Fisher Scientific). Peptides were then eluted from a 75 μm × 250 mm, 4 μm particle Jupiter Proteo C12 analytical column (Phenomenex, Torrance, CA, USA) at 350 nL·min^−1^ using 5--22% B over 70 min then to 35% B over 20 min and to 85% B over 15 min. Total run time was 2 h/sample. Data were acquired over mass range 300--1600 in a data‐dependent manner. Each full MS scan was followed by MS/MS of the 15 most abundant ions. Dynamic exclusion and repeat settings ensured each ion was selected only once and excluded for 30s thereafter.

MS data were analyzed using [maxquant]{.smallcaps} version 1.4.0.1 (Cox and Mann, [2008](#mol212463-bib-0014){ref-type="ref"}). The proteins were identified by searching MS and MS/MS data of peptides against the SWISS‐PROT human canonical database (20 556 entries) appended with common contaminants using the Andromeda search engine. Oxidation of methionine and protein N‐terminal acetylation was chosen as variable modifications. The minimum peptide length was specified to be seven amino acids. The initial maximal mass tolerance in MS mode was set to 7 ppm, whereas fragment mass tolerance was set to 0.5 Da for fragmentation data. The maximum false protein and peptide discovery rate (FDR) were specified as 0.01 and determined using a decoy database. Proteins were identified with ≥2 peptides/protein.

2.5. Estimation of laser microdissected sample purity {#mol212463-sec-0007}
-----------------------------------------------------

We attempted to estimate the degree of contamination based on the assumption that for a neuronal protein, for example, the level of expression in the PNI cancer relative to the invaded nerves is indicative of the degree of contamination of cancer sample by the adjacent nerve. We identified four known neuronal markers in the nerves dataset: glial fibrillary acidic protein (GFAP), S100B, neurofilament heavy polypeptide (NEFH), and neurosecretory protein VGF. We first calculated the abundance of each protein relative to the sample in which it was identified (for both PNI cancer samples and invaded nerves samples). The obtained value for each protein in the PNI cancer sample was then expressed as a percentage of its abundance in the matching invaded nerve sample. While most of these proteins were not detected in most PNI cancer samples, the relative abundance varied between the four proteins in the same sample pair (PNI cancer and invaded nerve) as well as for the same protein in different sample pairs particularly for GFAP.

We then used the relative abundance of the four proteins in each sample pair to estimate the degree of contamination of the PNI cancer sample by the matching invaded nerves' sample. We were not able to identify any epithelial‐specific protein in the invaded nerves samples to attempt a similar approach to estimate purity of invaded nerves samples.

2.6. Immunohistochemistry {#mol212463-sec-0008}
-------------------------

Basic clinico‐pathological data of FFPE tissue samples used for Immunohistochemistry (IHC) analysis are summarized in Table [S1](#mol212463-sup-0006){ref-type="supplementary-material"}. Four‐micrometer tissue sections were stained using rabbit anti‐SCG2 primary antibody (dilution 1 : 500 HPA011893 Prestige Antibodies, Sigma‐Aldrich) and anti‐VGF primary antibody (1/400 dilution, Abcam ab69989; Milton, Cambridge, UK). SCG2 IHC was performed in Ventana Discovery automated system, while VGF was performed manually with Vectastain ABC kit (Vector Labs, Peterborough, UK) according to the manufacturer\'s instructions. Staining intensity was semiquantitatively assessed at 200× magnification as absent (0), weak (1), moderate (2), or strong (3).

2.7. Western blotting {#mol212463-sec-0009}
---------------------

Cell lysis was performed using NP‐40 buffer (1% NP‐40, 50 m[m]{.smallcaps} Tris pH 7.4, 150 m[m]{.smallcaps} NaCl) with protease inhibitors (Roche Diagnostics, West Sussex, UK). Twenty‐five micrograms of protein lysate was analyzed by SDS/PAGE as previously described (Whiteman *et al*., [2007](#mol212463-bib-0062){ref-type="ref"}).

Following antibodies were used: goat anti‐VGF (Santa Cruz, R‐15:sc‐10383; Germany) 1 : 800; rabbit anti‐GAP43 (Abcam ab16053, Milton) 1/20 000; mouse anti‐GAPDH (Santa Cruz, Germany) 1/20 000; mouse anti‐Nestin, (Abcam, Milton), 1 : 200; and rabbit anti‐Caspase 3 ( Cell Signaling, 9662S; Leiden, the Netherlands) 1 : 400). Band intensities were quantified in [imagej]{.smallcaps} (National Health Institute, <https://imagej.nih.gov/ij/>) relative to the intensity of the GAPDH in the same sample. Densitometry results of three independent experiments were expressed as a fold change relative to the control samples.

2.8. PC12 co‐culture experiments {#mol212463-sec-0010}
--------------------------------

For the Transwell co‐cultures, 1.5 × 10^5^ PC12 cells were seeded in complete RPMI media in 6‐well plate precoated with PDL. 1.5 × 10^5^ PDAC or PC12 cells were also seeded in their respective media in 6‐well plate inserts (1 μm pore size, BD Biosciences, San Jose, CA, USA) in separate plates. On the next day, media was removed and cells in inserts and wells were washed three times with serum‐free RPMI. Inserts with PC12 or PDAC cells were then combined with wells containing PC12 cells before adding serum‐free RPMI to wells (2 mL) and inserts (1 mL). Twenty four hours later, phase‐contrast photographs of PC12 cells in the wells were taken using an inverted Olympus CKX41 microscope (Olympus, Hamburg, Germany) at 200× magnification. PC12 cells were then harvested for RNA and protein extraction and flow cytometry.

For the contact co‐cultures, 1.2 × 10^6^ PC12 cells were seeded in their complete RPMI media in T75 flasks precoated with PDL. On the next day, media was removed and cells were incubated with fresh media containing 2.5 μ[m]{.smallcaps} CellTracker Green CMFDA (Invitrogen, Loughborough, UK) at 37° for 30 min. Cells were then washed twice with serum‐free RPMI media and 1.2 × 10^6^ PDAC, or PC12 cells in complete RPMI media were added to the flasks. The added cells were then allowed to attach for 2 h. Co‐cultures were washed three times before adding 24 mL of fresh serum‐free RPMI. After 22 h, cells were harvested, and CMFDA‐positive PC12 cells were separated using FACS. The positively sorted cells were checked again using FACS to verify purity, and an aliquot of those cells was seeded on coverslips for additional immunocytochemical validation of their purity.

Seeding density (\~15 000 cells/1 cm^2^), ratio of PDAC to PC12 cells (1 : 1), and ratio of media to cells (1 mL/1.0 × 10^5^) were kept constant, and both co‐cultures were performed and analyzed in parallel

2.9. Preparation of conditioned media {#mol212463-sec-0011}
-------------------------------------

Conditioned media were prepared from 4 × 10^6^ PDAC or PC12 cells after an overnight culture. Cells were washed three times before adding fresh serum‐free RPMI for conditioning. Twenty‐four hours later, media were collected, centrifuged at 4000 ***g*** for 5 min, filtered (0.22‐μm filters, Millipore, Cork, Ireland), and immediately used to treat PC12 cells.

2.10. Quantitation of PC12 neurite growth {#mol212463-sec-0012}
-----------------------------------------

Randomly selected high‐power fields (three per well, at 200× magnification) of PC12 were analyzed for neurite growth in [imagej]{.smallcaps}. The degree of neurite extension was estimated by counting the number of cells bearing neurites longer than the maximum diameter of the cell body (Katoh *et al*., [2000](#mol212463-bib-0025){ref-type="ref"}). At least 200 cells were counted in each well, and results were expressed as percentage of total number of cells. Each experiment was performed at least three times.

2.11. Annexin V/DAPI flow cytometry assay {#mol212463-sec-0013}
-----------------------------------------

Floating and attached cells were harvested, centrifuged, and washed with ice‐cold PBS, pelleted and resuspended in 100 μL Annexin binding buffer (10 m[m]{.smallcaps} HEPES, 140 m[m]{.smallcaps} NaCl, 2.5 m[m]{.smallcaps} CaCl~2~, pH 7.4) containing 5 μL of Annexin V Alexa Fluor 647 (Invitrogen). Following 15‐min incubation at room temperature in the dark, 400 μL of the binding buffer containing 1 μg·mL^−1^ 4′,6‐diamidino‐2‐phenylindole (DAPI) was added to each sample. Flow cytometry was immediately performed using BD Fortessa cell analyzer (BD Biosciences). PC12 cells growing in their complete media or serum‐free RPMI were included as negative and positive controls, respectively. Cells negative for both Annexin V and DAPI were quantified as the surviving fraction, and results were expressed relative to PC12 survival in complete media. Duplicate wells were analyzed within each experiment, and experiments were repeated three times.

2.12. RNA extraction, cDNA synthesis, and qRT--PCR {#mol212463-sec-0014}
--------------------------------------------------

Total RNA was extracted using RNAqueous kit (Ambion, CA, USA). 1 μg of total RNA was reverse‐transcribed using Quantitech reverse transcription kit (Qiagen, West Sussex, UK). qRT--PCR was performed using SYBR green method on an ABI7500 cycler (Applied Biosystems, CA, USA). All primers were obtained from PrimerDesign (Southampton, UK). The VGF primer sequences were as follows: forward 5′‐TGAGACTTTGACACCCTTATCC and reverse 5′‐GGAACCGCCCAGGAATGA. Run conditions were as follows: 50 °C for 2 min, 95 °C for 15 min followed by 40 cycles of 95 °C for 15 sec, 60 °C for 30 sec, and 72 °C for 1 min. Data are presented as fold change relative to control after normalization to the mean of housekeeping genes B2M and RPL13 (PrimerDesign proprietary primer sequences).

2.13. VGF silencing {#mol212463-sec-0015}
-------------------

SiRNA knockdown of VGF in PC12 cells was performed using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer\'s instructions. SiRNA targeting VGF (On‐Target plus pool) or nontargeting siRNA (Dharmacon, Fisher Scientific, UK) was used at 1 nM final concentration. This was optimized to block the induced VGF expression but to maintain the basal levels of VGF expression at 24 h. Media was removed 6 h later, and cells were washed three times before incubation with PDAC‐ or PC12‐conditioned media for 24 h.

2.14. Statistical analysis {#mol212463-sec-0016}
--------------------------

Differential expression of proteins was assessed with Student\'s t‐test using peak intensity values for label‐free relative quantitative analysis of the LC‐MS/MS data. For continuous data, Student\'s *t*‐test was used to compare means of data whereas ANOVA with post hoc correction for multiple comparisons was used when three or more samples were compared. For semiquantitative IHC data, Mann--Whitney test was used to compare the means, whereas Kruskal--Wallis test with post hoc correction for multiple comparisons was used when comparing more than two groups. Two‐tailed *P* values were always calculated, and results were plotted as mean ± standard error of mean (SEM). The statistical analysis was performed using [graphpad prism]{.smallcaps} 5.03 software (San Diego, CA, USA). The significance level was set at *P* \< 0.05.

3. Results {#mol212463-sec-0018}
==========

3.1. Proteomic analysis of cancer cells and nerves in PNI {#mol212463-sec-0019}
---------------------------------------------------------

In order to assess the molecular alterations in cancer cells within the perineural environment, LC‐MS/MS analysis was performed on five matched PNI (cancer invading nerves) and non‐PNI (primary) cancer samples (Table [S1](#mol212463-sup-0006){ref-type="supplementary-material"}). The estimated purity of the microdissected PNI cancer samples based on the average relative abundance of four neuronal marker proteins was 98 and 96% for PNI‐1 and PNI2, respectively, and ≥99% for the last three samples. We could not identify any epithelial‐specific markers in the nerve samples to assess the degree of their contamination, which would suggest even higher degree of purity of those samples.

A total of 1628 nonredundant proteins were identified (Table [S2](#mol212463-sup-0007){ref-type="supplementary-material"}), of which 1432 proteins were seen in perineural cancer cells from the PNI samples (1083--1266 per sample) and 1542 proteins in cancer cells from the non‐PNI samples (1092--1258 per sample). Only 31 proteins (1.9%) were differentially expressed (*P* ≤ 0.05) (Table [S3](#mol212463-sup-0008){ref-type="supplementary-material"}); when a fold change of ≥1.5 was applied in addition to the *P* value, only eight up‐regulated and 11 down‐regulated proteins were identified. Using unsupervised hierarchical cluster analysis based on all identified proteins, PNI and non‐PNI samples obtained from each case were shown to cluster together, confirming further the similar nature of these samples (Fig. [1](#mol212463-fig-0001){ref-type="fig"}A). In parallel, LC‐MS/MS analysis of invaded and noninvaded nerve samples from the same five PDAC cases resulted in identification of 923 unique proteins (Table [S4](#mol212463-sup-009){ref-type="supplementary-material"}). In the invaded nerves, 847 proteins (681--729 proteins per sample) and in the noninvaded nerves 833 proteins (578--729 proteins per sample) were identified; 167 proteins (18%) were found differentially expressed (*P* ≤ 0.05) (Table [S5](#mol212463-sup-0010){ref-type="supplementary-material"}). A list of 61 differentially expressed proteins selected for both *P* ≤ 0.05 and fold change of ≥2 is provided in Table [1](#mol212463-tbl-0001){ref-type="table"}. Interestingly, unsupervised hierarchal clustering revealed that all invaded nerves (IN1‐5) were grouped together and were separated from the four out of five noninvaded nerves (NIN2‐5) (Fig. [1](#mol212463-fig-0001){ref-type="fig"}B). This clustering pattern strongly suggested common underlying molecular changes upon neural invasion. While the reason for clustering of one of the noninvaded nerve samples, NIN‐1, with invaded nerves could potentially be due to invasion of those nerves at a different depth in the tissue sample (or even in the adjacent tissue block), the observed clustering pattern strongly suggested common underlying molecular changes upon neural invasion.

![Hierarchal clustering of PNI and non‐PNI cancer samples (A) and invaded (IN) and noninvaded (NIN) nerve samples (B) according to their protein expression profiles. Each PNI sample clustered with its matching non‐PNI sample, while all invaded nerves clustered together. Only one noninvaded nerve grouped with invaded nerves. Clustering was performed using [arraytrack™]{.smallcaps} software (FDA, Silver Spring, MD, USA). Scale represents peak intensities.](MOL2-13-1075-g001){#mol212463-fig-0001}

###### 

List of proteins differentially regulated in invaded nerves compared to noninvaded nerves (two‐tailed Student\'s *t*‐test, *P* \< 0.05 and FC \> 2.0). The mean of peak intensity values from five samples is shown. IN: invaded nerves, NIN: noninvaded nerves, and FC, fold change

  Protein ID   Gene name   Protein name                                                                  IN            NIN           *P* value    FC
  ------------ ----------- ----------------------------------------------------------------------------- ------------- ------------- ------------ ---------
  P51659       HSD17B4     Peroxisomal multifunctional enzyme type 2                                     2.0E+06       0.0E+00       0            
  O00231       PSMD11      26S proteasome non‐ATPase regulatory subunit 11                               4.0E+06       0.0E+00       0.0001       
  P50440       GATM        Glycine amidinotransferase, mitochondrial                                     2.0E+06       0.0E+00       0.0005       
  P02647       APOA1       Apolipoprotein A‐I                                                            2.0E+08       6.0E+08       0.001        0.4
  P04040       CAT         Catalase                                                                      3.0E+07       6.0E+07       0.0012       0.4
  P59768       GNG2        Guanine nucleotide‐binding protein G subunit gamma‐2                          2.0E+07       7.0E+06       0.0017       2.3
  P11166       SLC2A1      Solute carrier family 2                                                       7.0E+06       5.0E+07       0.0036       0.2
  P07339       CTSD        Cathepsin D                                                                   6.0E+07       3.0E+07       0.0037       2.0
  Q8TAT6       NPLOC4      Nuclear protein localization protein 4 homolog                                2.0E+07       2.0E+06       0.004        8.1
  P54577       YARS        Tyrosine--tRNA ligase, cytoplasmic                                            2.0E+06       3.0E+05       0.004        7.6
  P48681       NES         Nestin                                                                        4.0E+08       1.0E+08       0.0048       3.4
  **P13521**   **SCG2**    **Secretogranin** II                                                          **3.0E+07**   **3.0E+06**   **0.0064**   **9.6**
  P19971       TYMP        Thymidine phosphorylase                                                       6.0E+07       2.0E+07       0.0064       2.4
  P08294       SOD3        Extracellular superoxide dismutase \[Cu‐Zn\]                                  3.0E+06       1.0E+07       0.0069       0.2
  Q00325       SLC25A3     Phosphate carrier protein, mitochondrial                                      8.0E+06       2.0E+06       0.0072       3.4
  P68871       HBB         Hemoglobin subunit beta; LVV‐hemorphin‐7                                      1.0E+09       8.0E+09       0.0078       0.2
  P01857       IGHG1       Ig gamma‐1 chain C region                                                     1.0E+08       3.0E+08       0.0079       0.4
  P21796       VDAC1       Voltage‐dependent anion‐selective channel protein 1                           1.0E+07       5.0E+06       0.008        2.4
  P02730       SLC4A1      Band 3 anion transport protein                                                6.0E+05       1.0E+07       0.0083       0.0
  **O15240**   **VGF**     **Neurosecretory protein VGF**                                                **1.0E+08**   **3.0E+07**   **0.0086**   **5.2**
  P24821       TNC         Tenascin                                                                      5.0E+07       2.0E+07       0.0088       2.6
  P11277       SPTB        Spectrin beta chain, erythrocyte                                              2.0E+05       2.0E+06       0.0098       0.1
  Q9HCJ6       VAT1L       Synaptic vesicle membrane protein VAT‐1 homolog‐like                          2.0E+07       5.0E+06       0.0111       2.8
  P45880       VDAC2       Voltage‐dependent anion‐selective channel protein 2                           1.0E+07       7.0E+06       0.0118       2.0
  Q9UHG2       PCSK1N      ProSAAS; KEP                                                                  3.0E+07       6.0E+06       0.0123       4.7
  P54920       NAPA        Alpha‐soluble NSF attachment protein                                          5.0E+06       2.0E+06       0.0123       2.2
  Q01484       ANK2        Ankyrin‐2                                                                     5.0E+07       2.0E+07       0.0126       2.1
  P36543       ATP6V1E1    V‐type proton ATPase subunit E 1                                              9.0E+06       4.0E+06       0.0133       2.3
  O15075       DCLK1       Serine/threonine protein kinase DCLK1                                         4.0E+06       9.0E+05       0.0142       4.3
  P06727       APOA4       Apolipoprotein A‐IV                                                           3.0E+07       7.0E+07       0.015        0.5
  Q9UI12       ATP6V1H     V‐type proton ATPase subunit H                                                6.0E+06       3.0E+06       0.0154       2.2
  P02042       HBD         Hemoglobin subunit delta                                                      1.0E+07       1.0E+08       0.0155       0.1
  P00918       CA2         Carbonic anhydrase 2                                                          5.0E+05       7.0E+06       0.0155       0.1
  Q9NTK5       OLA1        Obg‐like ATPase 1                                                             3.0E+06       7.0E+05       0.0169       3.5
  P69905       HBA1        Hemoglobin subunit alpha                                                      8.0E+08       4.0E+09       0.0179       0.2
  P61803       DAD1        Dolichyl‐diphosphooligosaccharide--protein glycosyltransferase subunit DAD1   4.0E+06       1.0E+06       0.019        3.8
  Q15063       POSTN       Periostin                                                                     1.0E+08       4.0E+07       0.0201       3.5
  P01834       IGKC        Ig kappa chain C region                                                       7.0E+07       2.0E+08       0.0202       0.4
  P17174       GOT1        Aspartate aminotransferase, cytoplasmic                                       2.0E+07       7.0E+06       0.0223       2.4
  P00915       CA1         Carbonic anhydrase 1                                                          7.0E+06       4.0E+07       0.0232       0.2
  P00450       CP          Ceruloplasmin                                                                 2.0E+07       5.0E+07       0.024        0.4
  P02790       HPX         Hemopexin                                                                     5.0E+07       9.0E+07       0.0266       0.5
  P17096       HMGA1       High mobility group protein HMG‐I/HMG‐Y                                       3.0E+07       6.0E+06       0.0271       5.2
  Q15631       TSN         Translin                                                                      3.0E+06       7.0E+06       0.0287       0.5
  P48163       ME1         NADP‐dependent malic enzyme                                                   2.0E+06       5.0E+05       0.0289       3.6
  Q16799       RTN1        Reticulon‐1                                                                   1.0E+07       5.0E+06       0.0307       2.5
  P17677       GAP43       Neuromodulin                                                                  2.0E+08       9.0E+07       0.0311       2.1
  O75348       ATP6V1G1    V‐type proton ATPase subunit G 1                                              9.0E+06       4.0E+06       0.034        2.1
  O00154       ACOT7       Cytosolic acyl coenzyme A thioester hydrolase                                 1.0E+07       4.0E+06       0.0342       2.8
  Q9NZN4       EHD2        EH domain‐containing protein 2                                                7.0E+06       5.0E+07       0.0347       0.1
  P00747       PLG         Plasminogen                                                                   7.0E+06       2.0E+07       0.0357       0.4
  P05156       CFI         Complement factor I                                                           1.0E+06       7.0E+06       0.0368       0.2
  O60716       CTNND1      Catenin delta‐1                                                               3.0E+06       5.0E+05       0.0374       6.3
  Q1KMD3       HNRNPUL2    Heterogeneous nuclear ribonucleoprotein U‐like protein 2                      2.0E+06       4.0E+05       0.0377       4.2
  P20591       MX1         Interferon‐induced GTP‐binding protein Mx1                                    8.0E+06       2.0E+06       0.0389       4.1
  P40121       CAPG        Macrophage‐capping protein                                                    1.0E+07       2.0E+06       0.0401       5.2
  Q01118       SCN7A       Sodium channel protein type 7 subunit alpha                                   4.0E+06       2.0E+07       0.0408       0.2
  Q86Y82       STX12       Syntaxin‐12                                                                   1.0E+06       0.0E+00       0.042        
  Q9P0J7       KCMF1       E3 ubiquitin--protein ligase KCMF1                                            3.4E+05       0.0E+00       0.0426       
  P05546       SERPIND1    Heparin cofactor 2                                                            2.0E+06       7.0E+06       0.0493       0.3
  P18509       ADCYAP1     Pituitary adenylate cyclase‐activating polypeptide                            7.0E+06       0.0E+00       0.0499       

Proteins in bold were selected for IHC validation.

John Wiley & Sons, Ltd

To identify enriched cellular functions and disease processes in invaded and noninvaded nerves, ingenuity pathway analysis (IPA) was performed. 'Neurological Diseases' was the most enriched disease category in addition to 'Immunological Diseases' and 'Inflammatory Response' (data not shown). Analysis of molecular and cellular functions revealed enrichment in 'Cell Death and Survival' (Fig. [S2](#mol212463-sup-0002){ref-type="supplementary-material"}A), as well as 'Cell Morphology', 'Cellular Growth and Proliferation' and 'Cell Movement' functions, including several subcategories related to neuritogenesis and axonal development, comprising proteins such as VGF, Neuromodulin (GAP43), Laminin B1 and C1 (LAMB1 and LAMC1), Tenascin (TNC), serine--threonine protein kinase DCLK1, and microtubule‐associated protein 1B (MAP1B) (Fig. [S2](#mol212463-sup-0002){ref-type="supplementary-material"}B).

3.2. Expression of SCG2 and VGF in the nerves {#mol212463-sec-0020}
---------------------------------------------

Two of the highly up‐regulated proteins in the invaded compared to noninvaded nerves (Table [1](#mol212463-tbl-0001){ref-type="table"}), secretogranin II (SCG2) and neurosecretory protein VGF, were selected for further validation by immunohistochemistry. In normal pancreas, strong expression of both proteins was seen in the islets, while nerves were mostly devoid of any immunoreactivity (Fig. [2](#mol212463-fig-0002){ref-type="fig"}A/G). Nerves in PDAC tissues, however, showed a spectrum of SCG2 and VGF expression; the nerves outside the tumor/stromal mass did not usually express VGF or SCG2 (Fig. [2](#mol212463-fig-0002){ref-type="fig"}B/H), and nerves within the tumor showed weak to moderate expression (Fig. [2](#mol212463-fig-0002){ref-type="fig"}C/I), while nerves invaded with cancer displayed in the majority of cases moderate to strong expression (Fig. [2](#mol212463-fig-0002){ref-type="fig"}D/J) that was significantly higher than in noninvaded nerves (Fig. [2](#mol212463-fig-0002){ref-type="fig"}E/K). Based on this observed pattern, we classified nerves into noninvaded extratumoral and intratumoral nerves and invaded nerves; both SCG2 expression and VGF expression were significantly different between these three groups (Fig. [2](#mol212463-fig-0002){ref-type="fig"}F/L). These data are consistent with the proteomic results and suggest a role for PDAC cells in the induction of both proteins in pancreatic nerves.

![The VGF (A--F) and SCG2 (G--L) expression in pancreatic cancer. Both proteins are highly expressed in islets (arrow) (A/G). Representative images of PDAC nerves (N) illustrated a range of immunoreactivity. Extratumoral nerves typically showed no VGF (B) and SCG2 (H) expression, whereas intratumoral noninvaded nerves were weakly to moderately positive (C/I); invaded nerves were strongly immunoreactive (D/J). VGF and SCG2 and expression were significantly higher in invaded compared to noninvaded nerves (E/K) and also significantly different between the three groups of nerves in PDAC (F/L). Scale bar = 50 μm; 2E/K, Mann--Whitney test, \*\*\**P* \< 0.001, 2F/L, Kruskal--Wallis test, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001; error bars indicate SEM;*n* = 50.](MOL2-13-1075-g002){#mol212463-fig-0002}

3.3. *In vitro* modeling of neuronal plasticity in PNI {#mol212463-sec-0021}
------------------------------------------------------

In order to further validate molecular changes observed in proteomic analysis and facilitate characterization of underlying molecular mechanisms in PNI, we established an *in vitro* co‐culture model, using PC12 cells as the neuronal element. PC12 is a rat pheochromocytoma cell line which on exposure to NGF differentiates into sympathetic‐like neurons, exits the cell cycle, extends neurites, and becomes electrically excitable (Greene and Tischler, [1976](#mol212463-bib-0022){ref-type="ref"}). As the pancreas is innervated chiefly by the autonomic nervous system (sympathetic and parasympathetic) in addition to the intrinsic pancreatic ganglia (Kiba, [2004](#mol212463-bib-0029){ref-type="ref"}; Salvioli *et al*., [2002](#mol212463-bib-0053){ref-type="ref"}), PC12 cells represent an attractive model for these nerves. All three tested PDAC cell lines, MiaPaca2, Capan1, and BxPc3, induced neurite extension in PC12 cells in the Transwell co‐culture system, similar to that induced by NGF (Fig. [3](#mol212463-fig-0003){ref-type="fig"}A, B). The same cell lines also protected PC12 cells from serum starvation‐induced apoptosis, as measured by Annexin V/DAPI (Fig. [3](#mol212463-fig-0003){ref-type="fig"}C, D). In agreement with this, we observed an abrogation in the levels of cleaved Caspase 3 (CASP3) in PC12 cells when co‐cultured with MiaPaca2, Capan1, and BxPc3 using the Transwell co‐culture system, which was comparable to the effect of NGF (Fig. [3](#mol212463-fig-0003){ref-type="fig"}E). These results indicate that PDAC cells were able to induce neuronal plasticity in PC12 cells similar to that observed in PNI.

![Neurite growth in Transwell co‐culture of PC12 cells with PDAC cell lines. PC12 co‐cultured on their own was used as controls. NGF (50 ng·mL^−1^) treatment was used as a positive control. Representative images of PC12 neurite growth in co‐culture with PDAC cell lines (A). Cells extending neurites longer than the maximum diameter of the cell body were counted and represented as a percentage of total number of cells (B). PC12 survival in transwell co‐cultures using Annexin V/DAPI flow cytometry assay. SF (serum‐free media) conditions were used as positive control for apoptosis, whereas CM (complete media) and NGF (50 ng·mL^−1^) were negative controls. Following 24 h co‐culture in serum‐free‐media, floating and attached PC12 cells were harvested, stained with Annexin and DAPI, and analyzed as detailed in Materials and methods section (C). The percentage of live cells (negative for both Annexin V and DAPI) in each condition was expressed relative to live cells in complete media (D). Western blot showing lower expression of Caspase 3 (E); scale bar = 50 μm; 3B/D, ANOVA, \*\*\**P* \< 0.001; error bars indicate SEM;*n* = 3.](MOL2-13-1075-g003){#mol212463-fig-0003}

Next, we assessed whether this model can also recapitulate the molecular changes seen in our proteomic analysis. In view of its role in neuronal plasticity (Alder *et al*., [2003](#mol212463-bib-0002){ref-type="ref"}), we tested VGF expression: Western blot showed twofold increase in VGF expression in PC12 cells co‐cultured with MiaPaca2, Capan1, and BxPC3 cells in the Transwell co‐cultures (Fig. [4](#mol212463-fig-0004){ref-type="fig"}A,B). Similar results were obtained at the mRNA level using qRT--PCR (Fig. [S3](#mol212463-sup-0003){ref-type="supplementary-material"}). We also investigated whether PDAC cell lines are able to induce the expression of other up‐regulated proteins in invaded nerves seen in our proteomic analysis, namely Neuromodulin (GAP43) and Nestin (NES), as they have been previously linked with neuronal plasticity and their expression shown to be increased in nerves in PDAC using IHC (Ceyhan *et al*., [2009a](#mol212463-bib-0008){ref-type="ref"}; Kawamoto *et al*., [2009](#mol212463-bib-0026){ref-type="ref"}; Lenz *et al*., [2011](#mol212463-bib-0033){ref-type="ref"}). Indeed, the expression of both proteins significantly increased in PC12 cells co‐cultured with Capan1 or BxPc3 cells (Fig. [4](#mol212463-fig-0004){ref-type="fig"}A,C,D).

![The VGF (A), Nestin, and GAP43 protein expression (C) in PC12 cells in Transwell co‐culture with PDAC cell lines or with PC12 as control. The representative western blots are shown. VGF appears as a doublet at \~80 and \~90 kDa, the lower band is thought to be a limited proteolytic product of the upper one (A). Densitometry analysis of three independent experiments (B, C, D). Bands are normalized to GAPDH as a loading control, and the results are expressed as fold change relative to control. 4B‐D, ANOVA, \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; error bars indicate SEM;*n* = 3.](MOL2-13-1075-g004){#mol212463-fig-0004}

Because our IHC analysis suggested a stronger induction of VGF immunoreactivity in the nerves as they come in close contact with cancer cells, we went on to verify whether *in vitro* contact co‐culture system could recapitulate this pattern of VGF expression. PC12 isolated from the contact co‐culture using FACS resulted in purity of the samples of 97% ±1.6 (mean ± SD) as estimated by FACS (Fig. [S4](#mol212463-sup-0004){ref-type="supplementary-material"}), and \>99% when estimated with anti‐CK19 antibody immunocytochemistry (Fig. [S5](#mol212463-sup-0005){ref-type="supplementary-material"}). Similar to the observation in Transwell co‐cultures, PDAC cell lines in the contact co‐culture protected PC12 cells from serum starvation‐induced apoptosis (Fig. [5](#mol212463-fig-0005){ref-type="fig"}A). Interestingly, approximately twofold increase in the induction of VGF in PC12 cells was seen in contact compared to Transwell co‐cultures (Fig. [5](#mol212463-fig-0005){ref-type="fig"}B,C). This is therefore reminiscent of VGF expression pattern observed in pancreatic nerves in the context of PDAC.

![PC12 cell contact co‐cultures. PC12 cell survival measured using Annexin V/DAPI flow cytometry assay in contact co‐culture (A) and VGF protein expression in both transwell and contact co‐cultures (B, C). 5A/C, ANOVA, \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; error bars indicate SEM;*n* = 3.](MOL2-13-1075-g005){#mol212463-fig-0005}

As VGF is known to play a role in cell survival (Severini *et al*., [2008](#mol212463-bib-0054){ref-type="ref"}) and neuronal plasticity (Alder *et al*., [2003](#mol212463-bib-0002){ref-type="ref"}), and its expression appears to mirror PC12 survival and neurite extension, we next tested whether VGF could mediate some of these phenotypic changes *in vitro*. While targeting VGF with specific siRNA successfully blocked its up‐regulation (Fig. [6](#mol212463-fig-0006){ref-type="fig"}A), this had no repercussion on survival of PC12 cells (Fig. [6](#mol212463-fig-0006){ref-type="fig"}B). However, PDAC cell‐induced neurite extension in PC12 cells was significantly attenuated after blocking VGF induction (Fig. [6](#mol212463-fig-0006){ref-type="fig"}C,D), indicating a functional role for VGF in the observed neuronal plasticity.

![Prevention of VGF induction in PC12 cells using siRNA silencing. Western blot confirming the maintenance of baseline levels of VGF upon conditioned medium (CnM) following siRNA (A). PC12 cell survival (using Annexin V/DAPI flow cytometry) (B), representative pictures of PC12 cell neurite extension (C), and quantification of the neurite extension (D) following VGF siRNA or nontargeting siRNA treatment. Scale bar = 50μm; 6B/D, ANOVA, \**P* \< 0.05; error bars indicate SEM;*n* = 3.](MOL2-13-1075-g006){#mol212463-fig-0006}

Taken together, data from our co‐culture system corroborate the proteomic profiling and IHC findings, confirm the ability of PDAC cells to induce neuronal plasticity, and reveal a functional role for VGF in this neuro‐epithelial interaction.

4. Discussion {#mol212463-sec-0022}
=============

Combining laser microdissection and proteomic approach has enabled us to perform the first direct characterization of the protein alterations in both cancer cells and nerves in the context of PNI in human PDAC. In the studies that investigated PNI and non‐PNI cancer cells using human tissues from cancers other than PDAC (Chen *et al*., [2007](#mol212463-bib-0011){ref-type="ref"}; Prueitt *et al*., [2008](#mol212463-bib-0043){ref-type="ref"}), a small number of differentially regulated genes were reported (none of these are in common with our proteomic data). While further in‐depth approach might be needed to reveal potentially subtler proteomic changes in cancer cells upon PNI in PDAC, these previous reports are confirmatory of largely similar profiles in PNI and non‐PNI cancer seen in our study.

In contrast, the analysis of the invaded and noninvaded nerves in PDAC revealed significant changes in their proteomic profiles, which *in silico* analysis highlighted to be a manifestation of neuronal plasticity. Interestingly, several up‐regulated proteins found here, including VGF and GAP43, pituitary adenylate cyclase‐activating polypeptide (ADCYAP1), Laminin A (LAMA), Nestin (NES), and TNC, have previously been shown to be up‐regulated in peripheral nerve injury (Costigan *et al*., [2002](#mol212463-bib-0013){ref-type="ref"}; Kim *et al*., [2009](#mol212463-bib-0031){ref-type="ref"}; Matsumura *et al*., [2010](#mol212463-bib-0040){ref-type="ref"}; Valder *et al*., [2003](#mol212463-bib-0060){ref-type="ref"}) and thus provide a molecular basis of the long‐described electron microscopy finding of nerve injury present within PNI (Bockman *et al*., [1994](#mol212463-bib-0006){ref-type="ref"}).

We identified several extracellular proteins as up‐regulated in invaded compared to noninvaded nerves (some of these were also seen in PNI compared to non‐PNI cancer), including laminins LAMA2, LAMB1, COL6A3, periostin (POST), nidogen 1 (NID1), and TNC. These are constitutive components of the extracellular milieu/matrix within which cancer cells and nerves are interacting, and some of them have dual roles in promoting both cancer growth and neurogenesis. This supports the concept that the PNI environment offers beneficial growth conditions for both cancer and nerves (Mancino *et al*., [2011](#mol212463-bib-0038){ref-type="ref"}).

Our proteomic analysis and IHC validation highlighted an increased expression of SCG2 and VGF in invaded compared to noninvaded nerves. Interestingly, the expression of both proteins increased as the nerves became closer to the cancer, which is consistent with previous observation of increasing neuroplasticity depending on the proximity of nerves to cancer (Ceyhan *et al*., [2010](#mol212463-bib-0010){ref-type="ref"}). SCG2 (secretogranin II, chromogranin C) is \~ 71‐kDa protein that belongs to the chromogranin--secretogranin family of acidic glycoproteins; it is expressed in secretory granules in a wide variety of peptide‐secreting cells throughout central nervous system, in scattered endocrine cells in stomach and duodenum and in pancreatic islets, as well as in neuronal elements throughout the intestinal wall (Boonen *et al*., [2007](#mol212463-bib-0007){ref-type="ref"}; Rosa *et al*., [1985](#mol212463-bib-0048){ref-type="ref"}). It is a principal target of REST (RE‐1 silencing transcription factor), an important regulator of neuronal differentiation which controls neurogenesis by preventing the differentiation of neural stem cells (Kim *et al*., [2015](#mol212463-bib-0030){ref-type="ref"}). SCG2 is a precursor for several peptides. One of them, EM66, is a 66‐amino acid anorexigenic neuropeptide that might be involved in regulation of feeding behavior and energy balance (Trebak *et al*., [2017](#mol212463-bib-0059){ref-type="ref"}); a 33‐amino acid neuropeptide called secretoneurin, on the other hand, promotes neurite outgrowth and repair of neuronal tissues (Shyu *et al*., [2008](#mol212463-bib-0057){ref-type="ref"}).

Similarly, VGF is expressed in both central and peripheral nervous system as well as in neuroendocrine cells in the gut (Levi *et al*., [2004](#mol212463-bib-0034){ref-type="ref"}; Lewis *et al*., [2015](#mol212463-bib-0035){ref-type="ref"}; Rindi *et al*., [2007](#mol212463-bib-0047){ref-type="ref"}; Salton *et al*., [2000](#mol212463-bib-0052){ref-type="ref"}). Its expression is regulated by neurotrophins during synaptic remodeling and axonal sprouting, and it is implicated in neuronal cell survival and plasticity (Alder *et al*., [2003](#mol212463-bib-0002){ref-type="ref"}; Severini *et al*., [2008](#mol212463-bib-0054){ref-type="ref"}; Shimazawa *et al*., [2010](#mol212463-bib-0056){ref-type="ref"}). Furthermore, akin to SCG2, VGF is also cleaved into several biologically active neuropeptides, expression of which varies between different tissues. Several VGF peptides were demonstrated to regulate nutrition and energy homeostasis, metabolism, and body weight (Bartolomucci *et al*., [2007](#mol212463-bib-0005){ref-type="ref"}; Watson *et al*., [2005](#mol212463-bib-0061){ref-type="ref"}). Furthermore, a central mechanistic role of VGF in neuropathic hypersensitivity and neuropathic pain has also recently been established (Ferri *et al*., [2011](#mol212463-bib-0021){ref-type="ref"}; Moss *et al*., [2008](#mol212463-bib-0041){ref-type="ref"}; Riedl *et al*., [2009](#mol212463-bib-0046){ref-type="ref"}), and it remains to be seen if VGF can be involved in generation of pain in PDAC patients as well.

Interestingly, this additional layer of functional complexity due to production of physiologically active peptides from both SCG2 and VGF is probably also the case in PDAC, which is corroborated in our proteomic dataset by the up‐regulation of PCSK1 in invaded nerves (Table [1](#mol212463-tbl-0001){ref-type="table"}), a known modulator of prohormone convertase 1 (PC1), which in turn is an enzyme responsible for both SCG2 and VGF processing.

In order to establish a simple and reproducible *in vitro* model of PNI, we have co‐cultured PC12 cells with PDAC cell lines. We show that tested PDAC cell lines were able to recapitulate the major phenotypic features of neuronal plasticity observed in tissues, namely nerve cell survival and neuritogenesis. PC12 cells undergo apoptosis in serum‐free media; NGF, bFGF and cAMP, known inducers of VGF have been shown to protect these cells from serum starvation‐mediated apoptosis (Rukenstein *et al*., [1991](#mol212463-bib-0049){ref-type="ref"}). We have therefore explored this further. While in our *in vitro* conditions VGF did not appear to mediate the survival of PC12 cells, blocking VGF induction resulted in significant reduction in neurite extension induced by both MiaPaca2‐ and BxPc3‐conditioned media. This indicated that while VGF is induced as part of the neuroplasticity response, being a secreted protein, it may also augment this process in an autocrine/paracrine fashion. While these experiments serve as a proof of principle and initial validation of usefulness of our *in vitro* model, further mechanistic studies detailing the roles of VGF (as well as SCG2) in PNI are now warranted.

Importantly, our model recapitulated several molecular changes observed in the proteomic analysis. PDAC cells were able to induce VGF expression mimicking the VGF induction in human tissues and also demonstrated their ability to up‐regulate VGF independently of any stromal influence. Interestingly, the up‐regulation of VGF in PC12 cells was even higher when they were in direct contact with cancer cells, which could be due to either exposure of PC12 cells to locally higher concentration of soluble paracrine factors or direct cell‐to‐cell communication. In addition to VGF, PDAC cell lines were also able to induce GAP43 as well as NES expression in PC12 cells, which was again consistent with our proteomic data. Both proteins have been shown previously by IHC to be expressed in nerves in PDAC (Ceyhan *et al*., [2009a](#mol212463-bib-0008){ref-type="ref"}; Kawamoto *et al*., [2009](#mol212463-bib-0026){ref-type="ref"}; Lenz *et al*., [2011](#mol212463-bib-0033){ref-type="ref"}). The induction of NES is particularly interesting, as it is a stem cell marker that is usually absent in adult postmitotic neuronal cells, indicating dedifferentiation response to nerve injury; its up‐regulation is also correlated with pain (Ceyhan *et al*., [2009b](#mol212463-bib-0009){ref-type="ref"}).

The functional and molecular alterations in PDAC cells in our co‐culture system still remain to be investigated. However, the flexibility of this model with regard to introducing different cellular components, performing gene manipulation and ease of collecting sufficiently large quantities of conditioned media from both cancer and PC12 cells (or any additional stromal or immune cellular component) can undoubtedly facilitate such investigations and underscores the advantages of this model when compared to primary neuronal cells and neural tissue explants. It would now be interesting to further develop this culture as a 3D model.

5. Conclusions {#mol212463-sec-0023}
==============

Here, we report on the first proteomes of both epithelial and neural components of PNI in human tissues and show that nerves invaded by pancreatic cancer undergo dramatic changes, manifested in neuronal plasticity, consistent with nerve injury. Some of the former changes were further successfully recapitulated in the developed *in vitro* co‐culture model, indicating a complex and intricate neuro‐epithelial crosstalk instigated during perineural invasion in pancreatic cancer.
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**Fig. S1**. Samples collected by laser microdissection. Matched PNI cancer cells, non‐PNI cancer cells, invaded nerves and non‐invaded nerves were laser microdissected from each of the five PDAC FFPE tissues. Top panel: before dissection; lower panel: verification of the dissected material.
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Click here for additional data file.

###### 

**Fig. S2**. Ingenuity Pathway Analysis of differentially regulated proteins in the nerve samples showing neuritogenesis‐related functions and the proteins contributing to those functions (A) and several proteins contributing to the activation of cell survival and inhibition of apoptosis (B). Colours of the nodes reflect the level of activation/inhibition according to the colour key. The first number below the protein name indicates the p‐value and the second a fold change. The four arrows that connect the nodes illustrate the Predicted relationships in the functional networks: orange/blue, when leading to activation/inhibition of the downstream node (e.g.protein); yellow indicates that the found relationship in the submitted data are inconsistent with the prediction based on Ingenuity Knowledge Base; grey color indicates that no predictions could be made from our proteomics data based on Ingenuity Knowledge Base.
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Click here for additional data file.

###### 

**Fig. S3**. VGF gene expression in PC12 cells co‐cultured with indicated PDAC cell lines. Values are relative to PC12 only co‐culture. ANOVA, \*p\<0.05, \*\*p\<0.01; error bars indicate SEM; n=3.
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Click here for additional data file.

###### 

**Fig. S4**. . Representative example of FACS sorting of contact co‐cultures to isolate PC12 cells (P4, CMFDA stained) **(A).** Sorted PC12 cells were checked again using FACS to verify their purity **(B).**
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Click here for additional data file.

###### 

**Fig. S5**. Immunocytochemistry staining of post‐sorted PC12 cells using anti‐CK19 antibody. Representative images (×400 magnification) of post‐sorted PC12 cells (right panel), the lack of CK19 staining indicates high degree of purity. PC12 cells and PDAC cells on their own were used as negative and positive controls, respectively (left panel). DAPI was used to stain nuclei.
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Click here for additional data file.

###### 

**Table S1**. Clinical details of PDAC cases used for laser microdissection (highlighted in light green) and proteomics analysis. TNM: tumor size, lymph node, distant metastases. UICC: Union for International Cancer Control.

###### 

Click here for additional data file.

###### 

**Table S2**. List of 1,628 non‐redundant proteins identified in cancer invading the nerves (PNI 1‐5) and non‐invading cancer (non‐PNI 1‐5).

###### 

Click here for additional data file.

###### 

**Table S3**. List of differentially expressed proteins in invasive and non‐invasive cancer. PNI: invasive cancer in the nerves, non‐PNI cancer not invading nerves. FC: fold change. Two‐tailed student\'s t‐test.

###### 

Click here for additional data file.

###### 

**Table S4**. List of 923 non‐redundant proteins identified in invaded (IN 1‐5) and non‐invaded (NIN 1‐5) nerves.

###### 

Click here for additional data file.

###### 

**Table S5**. List of proteins up‐regulated in invaded nerves compared to non‐invaded nerves. FC: fold change. Two‐tailed student\'s t‐test.

###### 

Click here for additional data file.
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